Table 3.
Multivariate analysis graft versus host disease, non relapse mortality and cumulative incidence of relapse.
| NRM | |
|---|---|
| HR [95% CI] p value | |
| Patient age per 1 yr increase | 1.048 [0.976, 1.120] 0.20 |
| ATLG-30 vs ATLG-15 | 0.398 [0.122, 1.300] 0.13 |
| DRSS High-risk vs Low-risk | 0.631 [0.176, 2.250] 0.48 |
| CIR | |
| HR [95% CI] p value | |
| Patient Age (per 1 yr increase) | 1.021 [0.994, 1.050] 0.12 |
| ATLG-30 vs ATLG-15 | 1.314 [0.661, 2.610] 0.44 |
| Donor Sex: Female vs Male | 0.854 [0.450, 1.620] 0.63 |
| DRSS: Intermediate 1 vs Standard | 0.947 [0.287, 3.120] 0.93 |
| DRSS: Intermediate 2 vs Standard | 1.133 [0.372, 3.450] 0.83 |
| DRSS: High vs Standard | 0.891 [0.193, 4.120] 0.88 |
| DRSS: Very High vs Standard | 3.370 [1.102, 10.310] 0.03 |
| TBI: TBI vs no TBI | 2.507 [1.040, 6.040] 0.04 |
| aGVHD24 | aGVHD34 | |
|---|---|---|
| HR [95% CI] p value | HR [95% CI] p value | |
| Patient age per 1 yr increase | 1.015 [0.987, 1.04] 0.300 | 1.023 [0.975, 1.07] 0.3600 |
| Year of Transplant per 1 yr increase | 1.018 [0.837, 1.24] 0.860 | 0.987 [0.698, 1.40] 0.9400 |
| ATLG-30 vs ATLG-15 | 0.708 [0.340, 1.47] 0.360 | 0.623 [0.216, 1.79] 0.3800 |
| Patient CMV serology pos vs neg | 2.403 [1.303, 4.43] 0.005 | 1.608 [0.652, 3.97] 0.3000 |
| Donor sex Female vs Male | 1.747 [0.959, 3.18] 0.068 | 1.388 [0.562, 3.43] 0.4800 |
| RIC vs MAC | 1.603 [0.859, 2.99] 0.140 | 5.893 [1.714, 20.26] 0.0049 |
| cGVHD all | cGVHD moderate/Severe | |
| HR [95% CI] p value | HR [95% CI] p value | |
| Patient age per 1 yr increase | 0.993 [0.976, 1.01] 0.48 | 1.004 [0.977, 1.031] 0.780 |
| Year of Transplant per 1 yr increase | 1.002 [0.880, 1.14] 0.98 | 0.922 [0.792, 1.073] 0.290 |
| ATLG-30 vs ATLG-15 | 0.810 [0.463, 1.41] 0.46 | 0.450 [0.214, 0.946] 0.035 |
| RIC vs MAC | 0.814 [0.474, 1.40] 0.46 | 1.185 [0.656, 2.141] 0.570 |
| No TBI vs TBI | 0.760 [0.334, 1.73] 0.51 | |
| CR vs not CR | 1.106 [0.649, 1.89] 0.71 | |
| CD34 Dose | 0.935 [0.851, 1.03] 0.15 |
CIR Cumulative Incidence of Relapse, NRM Non-Relapse Mortality, HR Hazard Ratio, CI Confidence Interval, CR Complete Remission, TBI Total Body Irradiation, aGVHD24 Acute Graft-versus-Host Disease (Grades 2–4), aGVHD34 Acute Graft-versus-Host Disease (Grades 3–4), cGVHD Chronic Graft-versus-Host Disease, ATLG Anti-T-Lymphocyte Globulin, RIC Reduced-Intensity Conditioning, MAC Myeloablative Conditioning, CMV Cytomegalovirus, CD34 Dose Infused CD34⁺ Cell Dose (×10⁶ cells/kg), DRSS Disease Risk Stratification System (Standard, Intermediate 1/2, High, Very High; grouped into Low-risk vs High-risk for NRM analysis).
Red: p < 0.05, Bold: p < 0.1.